128 related articles for article (PubMed ID: 27904670)
1. eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma.
Xue F; Liu Y; Chu H; Wen Y; Yan L; Tang Q; Xiao E; Zhang D; Zhang H
Am J Transl Res; 2016; 8(11):4670-4681. PubMed ID: 27904670
[TBL] [Abstract][Full Text] [Related]
2. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
[TBL] [Abstract][Full Text] [Related]
3. GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells.
Zhou QY; Tu CY; Shao CX; Wang WK; Zhu JD; Cai Y; Mao JY; Chen W
Am J Transl Res; 2017; 9(5):2608-2617. PubMed ID: 28560008
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma.
Lee NP; Tsang FH; Shek FH; Mao M; Dai H; Zhang C; Dong S; Guan XY; Poon RT; Luk JM
Int J Cancer; 2010 Aug; 127(4):968-76. PubMed ID: 19998337
[TBL] [Abstract][Full Text] [Related]
5. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation.
Wang X; Jiang R; Cui EH; Feng WM; Guo HH; Gu DH; Tang CW; Xue T; Bao Y
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1244-50. PubMed ID: 27097942
[TBL] [Abstract][Full Text] [Related]
6. Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression.
Xue F; Liu Y; Zhang H; Wen Y; Yan L; Tang Q; Xiao E; Zhang D
Onco Targets Ther; 2016; 9():7253-7261. PubMed ID: 27932893
[TBL] [Abstract][Full Text] [Related]
7. GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells.
Fang L; Gao L; Xie L; Xiao G
Oncol Rep; 2018 Mar; 39(3):1283-1291. PubMed ID: 29286162
[TBL] [Abstract][Full Text] [Related]
8. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species.
Liu RR; Lv YS; Tang YX; Wang YF; Chen XL; Zheng XX; Xie SZ; Cai Y; Yu J; Zhang XN
Oncotarget; 2016 Apr; 7(17):24348-60. PubMed ID: 27028999
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.
Tang DJ; Dong SS; Ma NF; Xie D; Chen L; Fu L; Lau SH; Li Y; Li Y; Guan XY
Hepatology; 2010 Apr; 51(4):1255-63. PubMed ID: 20112425
[TBL] [Abstract][Full Text] [Related]
10. Eukaryotic translation initiation factor 5A-2 involves in doxorubicin-induced epithelial-mesenchymal transition in oral squamous cell carcinoma cells.
Fang L; Gao L; Xie L; Xiao G
J Cancer; 2018; 9(19):3479-3488. PubMed ID: 30310504
[No Abstract] [Full Text] [Related]
11. MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.
Xue F; Liang Y; Li Z; Liu Y; Zhang H; Wen Y; Yan L; Tang Q; Xiao E; Zhang D
Oncol Lett; 2018 Jan; 15(1):813-820. PubMed ID: 29399149
[TBL] [Abstract][Full Text] [Related]
12. [Effects of cetuximab combined erlotinib on proliferation of human hepatocellular carcinoma cell lines HepG2 and Bel-7402].
Wei W; Guo RP; Li JQ; Xu L; Shi M; Zhang YQ
Ai Zheng; 2008 Apr; 27(4):386-92. PubMed ID: 18423125
[TBL] [Abstract][Full Text] [Related]
13. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation.
Yang J; Yu H; Shen M; Wei W; Xia L; Zhao P
Cancer Sci; 2014 Feb; 105(2):219-27. PubMed ID: 24262005
[TBL] [Abstract][Full Text] [Related]
14. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation.
Liu Y; Xue F; Zhang Y; Lei P; Wang Z; Zhu Z; Sun K
Anticancer Drugs; 2017 Nov; 28(10):1097-1105. PubMed ID: 28885268
[TBL] [Abstract][Full Text] [Related]
15. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
16. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
17. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
18. N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation.
Liu Y; Liu R; Fu P; Du F; Hong Y; Yao M; Zhang X; Zheng S
Cell Physiol Biochem; 2015; 36(6):2494-503. PubMed ID: 26279450
[TBL] [Abstract][Full Text] [Related]
19. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
[TBL] [Abstract][Full Text] [Related]
20. FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition.
Zhang Y; Lu Y; Zhang C; Huang D; Wu W; Zhang Y; Shen J; Cai Y; Chen W; Yao W
Int J Oncol; 2018 May; 52(5):1455-1464. PubMed ID: 29568938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
